Biological Safety Testing Products and Services Market Set for Strong Growth to USD 16.6 Billion by 2034 - SRI

London, UK - August 2026 | Strategic Revenue Insights Inc. - As biologics and biosimilars continue crowding pharmaceutical pipelines, the FDA and EMA have set high bars for biological safety testing that manufacturers cannot get around, and that regulatory pressure is now the primary force shaping how testing gets built, bought, and outsourced across the industry. Against that backdrop, the biological safety testing products and services market was valued at USD 6.5 billion in 2025 and is projected to reach USD 16.6 billion by 2034, growing at a CAGR of 11.00% between 2026 and 2034, according to a new report from Strategic Revenue Insights Inc. The findings are led by lead analyst Thomas Müller, and the report is built on primary interviews with pharmaceutical companies, biotechnology companies, contract research organizations, and contract manufacturing organizations, combined with secondary research spanning Asia Pacific, North America, Latin America, Europe, and Middle East & Africa.

Key Takeaways

• The biological safety testing products and services market is valued at USD 6.5 billion in 2025 and is forecast to reach USD 16.6 billion by 2034, at a CAGR of 11.00%.
• Reagents & Kits are the largest product and service segment, while Testing Services are the fastest-growing segment as outsourcing accelerates.
• Automation and digitalization are improving testing efficiency, accuracy, and turnaround times across high-throughput environments.
• North America leads the market, while Asia Pacific is witnessing the fastest growth.
• Charles River Laboratories, Merck KGaA, and Lonza are among the leading providers shaping the competitive landscape.

Full report access: https://www.strategicrevenueinsights.com/industry/biological-safety-testing-products-and-services-market

Regulatory Rigor and Expanding Biologics Pipelines Are Driving Testing Demand

The clearest driver behind this market is the combination of expanding biologics and advanced therapy pipelines and the stringent regulatory standards those pipelines must clear. As biologic drug development accelerates alongside the rising prevalence of chronic disease, every new product entering the pipeline requires rigorous safety testing before it can reach patients, and specialized manufacturing and development capacity is expanding in step with that pipeline growth. Sponsors are increasingly outsourcing development and testing work, converting fixed capital costs into variable spending and feeding directly into demand for third-party testing services.

Technology adoption is reinforcing this growth. Automated testing solutions are improving efficiency and accuracy while reducing human error, an important capability as companies handle larger sample volumes in high-throughput environments. Single-use and intensified processing technologies are also reducing changeover time and cross-contamination risk in testing workflows, while software solutions are increasingly used to manage data and support regulatory compliance across the testing lifecycle.

A third dynamic is the rise of personalized medicine and advanced therapies, which is creating demand for more specialized testing services. Cell and gene therapies in particular require rigorous, therapy-specific safety assessments to meet regulatory standards, and regional capacity-building programs are helping to reduce dependence on a small number of concentrated manufacturing geographies as this specialized testing demand spreads globally.

Market Segmentation

By product and service, Reagents & Kits dominate given their essential role across testing processes, while Testing Services are the fastest-growing category as companies increasingly outsource testing to specialized providers; Instruments and Software continue to expand as automation and data management needs grow.

By test type, Endotoxin Testing and Sterility Testing are critical components ensuring products are free from harmful contaminants and viable microorganisms, while Mycoplasma Testing and Bioburden Testing round out core quality assurance; Cell Line Authentication, Adventitious Agent Detection, and Residual Host Cell Protein & DNA testing are gaining importance as advanced therapies require more specialized safety assessments.

By application, Vaccines & Therapeutics represent a significant share of the market given rising demand for innovative treatments requiring rigorous testing, while Cell & Gene Therapy is experiencing rapid growth as regenerative medicine advances; Blood & Blood Products, Tissue Products, Stem Cell Products, and Medical Devices continue to require comprehensive safety testing to meet regulatory standards.

By end use, Pharmaceutical Companies are the largest end users given their reliance on comprehensive testing to meet regulatory standards, while Biotechnology Companies and Contract Research Organizations also depend heavily on advanced testing services; Academic & Research Institutes, Hospitals & Clinics, and Contract Manufacturing Organizations continue to expand their use of outsourced testing capacity.

Regional Outlook

North America is the largest regional market, supported by advanced healthcare infrastructure and high R&D investment, while Asia Pacific is witnessing the fastest growth, driven by increasing biopharmaceutical activity. Europe, Latin America, and the Middle East & Africa round out the report's regional coverage, each contributing to overall market expansion as biologics development and testing capacity continue to grow globally.

Competitive Landscape

Charles River Laboratories offers comprehensive testing solutions backed by a strong global presence and a focus on innovation and quality that has helped it maintain a competitive edge. Merck KGaA provides a wide range of testing products and services built to meet the evolving needs of the pharmaceutical and biotechnology sectors. Lonza is recognized for its comprehensive testing capabilities and global reach, positioning it among the market's established leaders in biological safety testing.

Market Restraints

The market's growth is tempered by the high cost of regulatory compliance, as companies must invest in robust testing methodologies and navigate complex frameworks imposed by bodies such as the FDA and EMA. The market is also exposed to potential supply chain disruptions, since companies rely on a complex global network of suppliers and distributors for critical testing reagents and instruments, leaving them vulnerable to geopolitical tensions and trade restrictions.

Related Reports

https://www.strategicrevenueinsights.com/industry/plant-based-energy-drink-market

https://www.strategicrevenueinsights.com/industry/prebiotics-and-probiotics-supplements-market

https://www.strategicrevenueinsights.com/industry/premium-bottled-water-market

https://www.strategicrevenueinsights.com/industry/pumpkin-seed-protein-fiber-market

https://www.strategicrevenueinsights.com/industry/soluble-milk-protein-market

Frequently Asked Questions

How big is the biological safety testing products and services market?

The market was valued at USD 6.5 billion in 2025 and is projected to reach USD 16.6 billion by 2034, growing at a CAGR of 11.00%.

What is driving growth in the biological safety testing products and services market?

Growth is driven by increasing demand for biologics, stringent regulatory requirements, and advancements in testing technologies.

Which region leads the biological safety testing products and services market?

North America is the largest regional market, while Asia Pacific is witnessing the fastest growth.

Who are the leading companies in the biological safety testing products and services market?

Leading companies named in the report include Charles River Laboratories, Merck KGaA, and Lonza.

About Strategic Revenue Insights Inc.

Strategic Revenue Insights Inc., part of SRI Consulting Group Ltd, is a London-headquartered market intelligence firm that helps organizations across industries and geographies make evidence-based revenue and strategy decisions. The firm produces syndicated research reports and customized consulting engagements built on rigorous market sizing, forecasting, and competitive benchmarking, drawing on a globally connected team of analysts and consultants.

Media Contact Information

Company Name: Strategic Revenue Insights Inc.

Contact Person: Rohit Bhisey

Email: sales@strategicrevenueinsights.com

Phone: +44-787-740-3352

Address: Suite 10, Capital House, 61 Amhurst Road, London, E8 1LL, United Kingdom

Corporate Websites:

www.strategicrevenueinsights.com

www.strategicpackaginginsights.com

www.sriconsultinggroupltd.com

https://strategicrevenueinsights.blog/

https://medium.com/@strategic-revenue-insights.inc

https://www.strategicrevenueinsights.com/press-releases